People prescribed Ozempic or Wegovy are less likely to develop a cannabis use disorder or relapse from the condition than those who take other diabetes or obesity medications, reported the NewScientist on Thursday. As brand names for the compound semaglutide, Ozempic and Wegovy are said to reduce appetite and regulate blood sugar levels. It is now routinely prescribed to treat type 2 diabetes and obesity, and some evidence suggests it eases cravings in substance use disorders, too, such as alcoholism or nicotine addiction. However, no studies have yet assessed whether semaglutide affects canna…